Kidney Cancer Weekly

February 16, 2026

Videos

Peer-to-Peer Clinical Conversations

Phase II Trial Compares PET Imaging to Conventional Scans Post-Nephrectomy - Brian Shuch

Brian Shuch

Pedro Barata is joined by Brian Shuch to discuss his investigator-initiated phase 2 trial evaluating girentuximab PET-CT imaging for detecting residual disease after nephrectomy in clear cell renal cell carcinoma.

View

Identifying the Right Patient for [⁸⁹Zr]Zr-Girentuximab PET–CT Imaging in Clear Cell RCC - Vitaly Margulis

Vitaly Margulis

Zachary Klaassen and Vitaly Margulis explore the emerging role of Girentuximab PET-CT in kidney cancer management.

View

Beyond the Abstracts

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

WSAUA 2025: Impact of Neoadjuvant Systemic Therapy on Tumor and Tumor Thrombus Regression in Renal Cell Carcinoma with Venous Involvement: A Retrospective Analysis

ESMO 2025: The Intratumor Mycobiome Promotes Clear Cell Renal Cell Carcinoma Progression via Neutrophil-Mediated Immune Suppression

ESMO 2025: Neoadjuvant Immunotherapy in Locally Advanced Clear Cell Renal Cell Carcinoma at Risk for Recurrence or Distant Metastases: The Randomized Phase II NESCIO Trial

ASTRO 2025: Ultra-Hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for Primary Renal Cell Carcinoma: Pooled Outcomes from the FASTRACK and FASTRACK II Clinical Trials

SCS AUA 2025: Contemporary Outcomes for Radical Nephrectomy with Inferior Vena Cava Thrombectomy in the Era of Pre-Operative Immunotherapy

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Histology-specific Prognostic Impact of Microscopic Positive Surgical Margins in Renal Cell Carcinoma: Implications for Postoperative Surveillance.

Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future?

ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma.

Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and mendelian randomization analysis.

Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.

Surgical Management of Nonmetastatic Renal Cell Carcinoma with Inferior Vena Cava Thrombus: A Systematic Review and Network Meta-analysis.

Deep Learning Identification of Clear Cell Renal Cell Carcinoma on MR Imaging.

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Percutaneous Biopsy and Recurrence Risk in Stage 1 Renal Cancer: A Propensity Score-Matched Cohort Study.

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

Kidney-Sparing Treatments for Local Recurrence in Renal Cell Tumours after Partial Nephrectomy or Focal Therapy: A Systematic Review - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login